1256359-09-7 Usage
General Description
1H-Indazole, 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- is a chemical compound that belongs to the indazole family, which is a class of organic compounds containing an indazole ring structure. This particular compound contains a methyl group at the 1-position and a boron-containing group at the 6-position of the indazole ring. The boron-containing group, specifically the dioxaborolane, is often used as a reagent in organic synthesis and as a protecting group for alcohols and amines. 1H-Indazole, 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- may have potential uses in medicinal chemistry, materials science, and other chemical applications due to its unique structure and properties. However, its specific uses and properties would depend on further research and testing.
Check Digit Verification of cas no
The CAS Registry Mumber 1256359-09-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,3,5 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1256359-09:
(9*1)+(8*2)+(7*5)+(6*6)+(5*3)+(4*5)+(3*9)+(2*0)+(1*9)=167
167 % 10 = 7
So 1256359-09-7 is a valid CAS Registry Number.
1256359-09-7Relevant articles and documents
4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF
-
Page/Page column 192; 193, (2017/01/09)
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDK12, or CDK13) or a lipid kinase such as a phosphatidylinositol- 5 -phosphate 4- kinase (PIP4K) (e.g., ΡΙ5Ρ4Κα, ΡΙ5Ρ4Κβ, or ΡΙ5Ρ4Κγ)) in the subject.
